NEW YORK ( TheStreet) -- CHANGE IN RATINGS
Hanesbrands (HBI) was initiated with a neutral rating at Goldman Sachs. $23 price target. Attractive business but facing several challenges.
ViroPharma (VPHM) was initiated with a buy rating at Brean Murray. $37 price target. Stregnth of orphan drug, Cinryze.Wabco (WBC) WBC was upgraded to overweight at JPMorgan. Unique buying opportunity.
STOCK COMMENTS / EPS CHANGESAlcoa (AA - Get Report) estimates lowered through 2011, Morgan Stanley said. Should retain defensive appeal despite headwinds. Overweight rating and $13 price target. Actuant (ATU) numbers raised at Jefferies. Shares of ATU now seen reaching $31, Jefferies said. High-quality first quarter and beat. Buy rating. Bed Bath & Beyond (BBBY) estimates increased through 2013, UBS said. Solid results and margin expansion. Maintain $64 price target and neutral rating. CVS Caremark (CVS - Get Report) target raised at Goldman Sachs. Shares of CVS now seen reaching $44, Goldman Sachs said. Revived credibility yields confidence in growth algorithm. Buy rating. Emerson Electric (EMR - Get Report) numbers lowered at UBS. Shares of EMR now seen reaching $50, according to UBS. Estimates also lowered on climate weakness and flat year-over-year orders. Neutral rating.
2012 Stock Predictions and Outlook
|Your one-stop shop for 2012 stock recommendations and market predictions.